RefleXion Announces First Patient Treatment at Leading Freestanding Cancer Center

Audio By Carbonatix

HAYWARD, Calif.--(BUSINESS WIRE)--Oct 9, 2025--

RefleXion, an external-beam, theranostic oncology company, today announced that Beverly Hills Cancer Center, a leading private cancer diagnostic and treatment facility, has treated its first patient with the RefleXion ® X1 dual-treatment modality radiotherapy platform. This milestone marks an important expansion of the X1’s clinical footprint into freestanding cancer centers, broadening patient access to both SCINTIX ® biology guided-radiotherapy and conventional image-guided radiotherapy (IGRT).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251009446356/en/

The RefleXion X1 is a dual-treatment modality platform that delivers both SCINTIX biology-guided radiotherapy for lung and bone tumors, and conventional image-guided radiotherapy for solid tumors located anywhere in the body.

“We are very pleased to have begun patient treatments on the RefleXion X1 platform,” said Ari Gabayan, M.D., medical director at Beverly Hills Cancer Center. “This dual-treatment platform enables us to treat all stages of solid tumor cancers in IGRT mode and to introduce a completely new therapeutic option using the autonomous guidance of SCINTIX therapy for patients with lung and bone tumors. SCINTIX technology is unlike any other radiotherapy, and we believe it represents the next frontier in precision cancer care.”

With this installation, Beverly Hills Cancer Center joins a growing network of cancer centers adopting RefleXion’s X1 platform to expand their radiotherapy capabilities. In addition to delivering conventional IGRT, Beverly Hills Cancer Center is preparing to offer SCINTIX therapy for patients with lung and bone tumors. SCINTIX therapy uses real-time biological signals emitted from cancer cells to autonomously guide radiation delivery. Patients receive an injection of a small amount of a PET tracer, fludeoxyglucose F18, which the cancer cells consume. The X1 detects the signals produced by the PET tracer and dynamically directs radiation dose to active tumor cells.

“With their first patient treatment on the X1 platform, Beverly Hills Cancer Center continues their strong tradition of delivering cutting-edge cancer treatment,” said Todd Powell, president and CEO of RefleXion. “This milestone underscores the scalability and adaptability of our technology, opening access to both hospital-based and freestanding centers. It also demonstrates the growing commercial potential of our platform as we move closer to establishing SCINTIX therapy as a new standard for metastatic disease.”

Recently, RefleXion announced positive results from its PREMIER registry a prospective, multi-institutional study evaluating SCINTIX therapy. Findings presented at the 2025 ASTRO Annual Meeting in San Francisco, showed local control of 100 percent via follow up imaging of up to nine months post-treatment with no reported Grade 2 or higher adverse events among 31 patients. Patients were treated for lung tumors, including early-stage and metastatic disease, or for bone metastases. These data represent the first evidence of SCINTIX therapy’s clinical impact.

About RefleXion Medical

RefleXion is a privately held theranostic oncology company located in Hayward, Calif., commercializing SCINTIX biology-guided radiotherapy, a novel therapy that uses a single radiotracer injection to turn cancer cells into real-time biological beacons to guide external-beam radiotherapy. SCINTIX therapy is FDA-cleared for FDG-guided treatment of lung and bone tumors, including metastases. The RefleXion X1 platform is also cleared for conventional image-guided radiotherapy for solid tumors located anywhere in the body. For more information, visit www.reflexion.com.

About Beverly Hills Cancer Center

Beverly Hills Cancer Center provides a unique model of exceptional care, integrating advanced clinical trials, cutting-edge diagnostics, and innovative treatments. With highly skilled physicians, a dedicated staff, and a tranquil healing environment, Beverly Hills Cancer Center is recognized as a leading private cancer diagnostic and treatment facility in Southern California and beyond.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251009446356/en/

CONTACT: Media Contacts

RefleXion

[email protected]

+1-650-239-9070Beverly Hills Cancer Center

Sharon Neman

[email protected]

+1-310-432-8925

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: RADIOLOGY BIOTECHNOLOGY ONCOLOGY GENERAL HEALTH HEALTH FDA MEDICAL DEVICES HEALTH TECHNOLOGY

SOURCE: RefleXion Medical

Copyright Business Wire 2025.

PUB: 10/09/2025 07:00 AM/DISC: 10/09/2025 07:02 AM

http://www.businesswire.com/news/home/20251009446356/en